Latest News Archive

Please select Category, Year, and then Month to display items

The New Face of Student Mental Wellness at the UFS

08 February 2022 | Story Anthony Mthembu | Photo Charl Devenish

Dr Munita Dunn-Coetzee has joined the University of the Free State as the new Director of Student Counselling and Development. This is after an eleven-year stay at Stellenbosch University as the Deputy Director of the Centre for Student Structures and Communities, and later as the Director of the Centre for Student Counselling and Development.

Dr Dunn-Coetzee’s role at the UFS

As leader of the department, Dr Dunn-Coetzee sees her role as one in which she is responsible for moving her team forward. “My role is to really look at what the team needs. This is from infrastructure right through to their own personal development, and to making sure that they have what they need to get their jobs done,” she stated. In addition, Dr Dunn-Coetzee’s responsibilities include, “looking at our strategic intent, aligning with what the university wants, being relevant in terms of our service delivery, and connecting enough with the students”. In fact, one of the things she is excited about is learning from the students at the University of the Free State. “The big thing for me is to make contact with students and to engage with them about what is going on at ground level; the one thing I don’t want to be is someone who sits in the office, sends emails, and think I know what’s going on,” she explained.

A commitment to the mental health of UFS students

Although her two predecessors were internal appointments, Dr Dunn-Coetzee argues that being an external appointment allows her to have a fresh perspective. As such, one of her main priorities for the year is looking at student leaders, day residences, residences on campus, and residential heads, and analysing whether they are empowered enough to have conversations about mental-health issues with students. “The one thing that concerns me is that we have been online for two years, and now that we are telling students to come back to campus, it might evoke a level of anxiety in some students,” she explained. Therefore, ensuring that the department is student-centred in everything it does is very important to Dr Dunn-Coetzee. This varies from the way in which students are dealt with, how emails are responded to, and how students are treated when they walk into the Kovsie Health Building.

A long-term vision for the department and the university

Even though she has not been at the University of the Free State for very long, Dr Dunn-Coetzee has some long-term goals that are bound to positively impact both the students and the staff in her department. “I would like to have a research focus within our department; it is very easy to say that we are doing good work and that we have an impact on our students, but we need to have something that proves it,” she said. Therefore, an evidence-based approach is one of the directions she would like to pursue in her department. In addition, Dr Dunn-Coetzee argues that there is a need for a space in which intern psychologists can be trained. “It keeps your current staff on their toes, and it helps you to really play a role in developing psychologists in South Africa,” she expressed. Therefore, opening this space for young psychologists is something she hopes to make a reality in her time at the university. Furthermore, developing her staff and ensuring that they grow their skill set is an important goal she would like to achieve. “My focus is not to have people work here for thirty years; I need to empower them so that they can develop as much as they can. Of course, I love having them here, but in the event that they want to work somewhere else I need to make sure that they are skilled,” she said. Lastly, a goal she is adamant to achieve is to ensure that the service delivery by Student Counselling and Development is of a high standard on all three campuses.

As such, Dr Dunn-Coetzee would like to be viewed by the student community as accessible and approachable. “I would like for students to walk in here and feel comfortable; it doesn’t matter what you identify as – there is a space for you here,” she said.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept